ZAI LAB (09688) announced on March 5, 2026, that Mr. Leon O. Moulder, Jr. has been re-designated as a director. He continues to serve on the Commercial Committee and the Research and Development Committee, drawing on his senior operational expertise in the biopharmaceutical industry and extensive board experience in both public and private companies.

Mr. Moulder is the Founder and Managing Member of a life sciences investment fund, Tellus Bio Ventures, LLC, and holds board positions with additional organizations, including Dianthus Therapeutics, Inc. and several Tellus portfolio companies. He also serves as Founder, Chief Executive Officer, and Chairman of the board of directors of Zenas BioPharma and previously held prominent leadership roles at multiple biopharmaceutical ventures.

Under the Company’s non-employee director compensation policy, Mr. Moulder is entitled to receive US$50,000 per year for Board service, an additional US$7,500 per year for service on the Commercial Committee, and an additional US$10,000 per year for service on the Research and Development Committee, along with annual equity compensation. He currently holds restricted shares covering 72,602 American Depositary Shares and does not have any other relationship with the Company’s directors, senior management, or major shareholders. He will hold office until the next annual general meeting and be eligible for re-election according to the Company’s articles of association.